Mediator release is altered in immunotherapy-treated patients: A 4-year study

被引:0
|
作者
Dokic, D [1 ]
Nethe, A [1 ]
KleineTebbe, J [1 ]
Kunkel, G [1 ]
Baumgarten, CR [1 ]
机构
[1] FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, DEPT CLIN IMMUNOL & ASTHMA, OPD, D-13353 BERLIN, GERMANY
关键词
immunotherapy; mediator release; specific IgG antibodies;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
In recent years, it has been possible to demonstrate mediator release into the nasal secretion after nasal allergen challenge in patients with allergic rhinitis. Using the nasal provocation model, we determined whether the mediator release was altered in immunotherapy-treated patients. Seventeen grass-pollen-allergic patients were examined under controlled, reproducible conditions. Serial challenges with increasing doses of grass pollen produced increasing numbers of clinical symptoms and release of mediators such as kinins, TAME-esterase activity and histamine. Ten patients received a semidepot perennial grass-pollen extract for 4 years. Seven patients served as controls and did not receive immunotherapy during the observation period. Data from the group of patients receiving immunotherapy over the first year already showed a partially significant decline in the maximal mediator release after nasal allergen challenges compared to the results of pretreated challenges, whereas controls did not show any significant changes. Nasal allergen challenges after termination of 4 years' immunotherapy significantly modified the mediator release compared to pretreatment values (TAME-esterase activity P < 0.05, kinins P < 0.01, and histamine P < 0.01). Decrease of mediator release paralleled the symptom-medication scores and quantitative skin prick test. Finally, we could demonstrate a significant correlation between specific IgG increase and mediator decrease in the treated group.
引用
收藏
页码:796 / 803
页数:8
相关论文
共 50 条
  • [41] BEHAVIORALLY TREATED IRRITABLE-BOWEL-SYNDROME PATIENTS - A 4-YEAR FOLLOW-UP
    SCHWARZ, SP
    TAYLOR, AE
    SCHARFF, L
    BLANCHARD, EB
    BEHAVIOUR RESEARCH AND THERAPY, 1990, 28 (04) : 331 - 335
  • [42] Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids
    Yan, Lei
    Kang, Pan
    Cao, Chengsong
    Jinhui, Bu
    Yong, Liu
    PLOS ONE, 2024, 19 (06):
  • [43] Teenage drinking: A 4-year comparative study
    Foxcroft, DR
    Lowe, G
    ListerSharp, DJ
    ALCOHOL AND ALCOHOLISM, 1995, 30 (06): : 713 - 719
  • [44] A 4-YEAR STUDY OF THE TREATMENT OF HYPERTHYROIDISM WITH METHIMAZOLE
    CHEVALLEY, J
    MCGAVACK, TH
    KENIGSBERG, S
    PEARSON, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1954, 14 (08): : 948 - 960
  • [45] A RANDOMIZED 4-YEAR STUDY OF PERIODONTAL THERAPY
    PIHLSTROM, BL
    ORTIZCAMPOS, C
    MCHUGH, RB
    JOURNAL OF PERIODONTOLOGY, 1981, 52 (05) : 227 - 242
  • [46] ANNUAL-MEETING - 4-YEAR STUDY
    COMERCI, GD
    COHEN, MW
    PREECE, EW
    PEDIATRIC RESEARCH, 1977, 11 (04) : 376 - 376
  • [47] Tuberculosis in Geneva: a 4-year retrospective study
    Kherad, O.
    Rochat, T.
    Janssens, J. -P
    SWISS MEDICAL WEEKLY, 2007, 137 : 10S - 10S
  • [48] PREPERITONEAL GROIN HERNIOPLASTY - 4-YEAR STUDY
    REAGAN, WN
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 1974, 73 (12): : 999 - 1002
  • [49] 4-YEAR STUDY OF THE TREATMENT OF HYPERTHYROIDISM WITH METHIMAZOLE
    MCGAVACK, TH
    CHEVALLEY, J
    PEARSON, S
    KENIGSBERG, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1954, 14 (07): : 801 - 801
  • [50] A 4-year study of Anaplasma phagocytophilum in Portugal
    Santos, A. S.
    Bacellar, F.
    Dumler, J. S.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 : 46 - 47